ArticleBreast cancer research and treatment2025
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.
Connie Lau et al.PubMed ↗Publisher ↗
No numbers read from the abstract.